| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Rakesh Jain | Q7286601 |
| Matthias Pinter | Q61144789 | ||
| P2093 | author name string | Matthias Pinter | |
| P2860 | cites work | 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q22241919 |
| Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy | Q86115091 | ||
| Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer | Q86732555 | ||
| Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients | Q87353406 | ||
| No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer | Q88336524 | ||
| The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs) | Q89137135 | ||
| Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy | Q89213409 | ||
| Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity? | Q38053539 | ||
| Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis | Q38112273 | ||
| Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward | Q38166896 | ||
| Immune evasion in cancer: Mechanistic basis and therapeutic strategies. | Q38394302 | ||
| Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma | Q38415959 | ||
| Metastatic colorectal cancer: current state and future directions | Q38445676 | ||
| Combination cancer immunotherapies tailored to the tumour microenvironment | Q38645178 | ||
| Immune suppressive mechanisms in the tumor microenvironment | Q38648567 | ||
| Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab | Q38718044 | ||
| Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis | Q38750495 | ||
| Ang-(1-7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway. | Q38898394 | ||
| Angiotensin (1-7) and Alamandine: Similarities and differences | Q38908058 | ||
| The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer | Q38956286 | ||
| Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma | Q38981634 | ||
| The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients | Q39028544 | ||
| The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice | Q39182740 | ||
| Angiotensin II induces angiogenic factors production partly via AT1/JAK2/STAT3/SOCS3 signaling pathway in MHCC97H cells | Q39344956 | ||
| Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. | Q39416206 | ||
| Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer | Q39463402 | ||
| The Association between Angiotensin Receptor Blocker Usage and Breast Cancer Characteristics | Q39470160 | ||
| Determinants of tumor blood flow: a review | Q39636842 | ||
| Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer. | Q39639537 | ||
| Expression of angiotensin-converting enzyme changes major histocompatibility complex class I peptide presentation by modifying C termini of peptide precursors | Q39646814 | ||
| Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. | Q39713490 | ||
| Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers | Q39749935 | ||
| Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth | Q39778121 | ||
| Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells | Q39789535 | ||
| Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. | Q39798527 | ||
| Angiotensin II induces oxidative stress in prostate cancer | Q40006746 | ||
| Decreased migration of myeloid dendritic cells through increased levels of C-reactive protein. | Q40019842 | ||
| Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling | Q40047817 | ||
| Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma | Q40281513 | ||
| Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. | Q40283559 | ||
| Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells | Q40353409 | ||
| Angiotensin II and epidermal growth factor induce cyclooxygenase-2 expression in intestinal epithelial cells through small GTPases using distinct signaling pathways | Q40496125 | ||
| Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo | Q40672073 | ||
| Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer | Q40738905 | ||
| Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. | Q40746660 | ||
| The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor | Q40811983 | ||
| Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients | Q40939536 | ||
| Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials. | Q41035635 | ||
| Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma | Q41686732 | ||
| The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration | Q41909578 | ||
| The response of tumour vasculature to angiotensin II revealed by its systemic and local administration to 'tissue-isolated' tumours | Q42590769 | ||
| Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma | Q42776799 | ||
| Myeloid expression of angiotensin-converting enzyme facilitates myeloid maturation and inhibits the development of myeloid-derived suppressor cells | Q42976469 | ||
| Angiotensin II drives the production of tumor-promoting macrophages | Q43239444 | ||
| Phase‐II trial of combination treatment of interferon‐α, cimetidine, cyclooxygenase‐2 inhibitor and renin‐angiotensin‐system inhibitor (I‐CCA therapy) for advanced renal cell carcinoma | Q43471481 | ||
| Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis | Q43662708 | ||
| Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. | Q43755028 | ||
| Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. | Q44300102 | ||
| The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer | Q44312258 | ||
| Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation | Q45020438 | ||
| Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth | Q45214758 | ||
| Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. | Q45980091 | ||
| Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer. | Q46018831 | ||
| The synergistic induction of cyclooxygenase-2 in lung fibroblasts by angiotensin II and pro-inflammatory cytokines | Q46337744 | ||
| Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer | Q46341615 | ||
| Ang II and EGF synergistically induce COX-2 expression via CREB in intestinal epithelial cells | Q46368695 | ||
| Oxidative stress in malignant melanoma enhances tumor necrosis factor-α secretion of tumor-associated macrophages that promote cancer cell invasion | Q46413110 | ||
| Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension | Q46819084 | ||
| Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer | Q46862408 | ||
| Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma | Q47106953 | ||
| Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. | Q47292033 | ||
| A comparative study of tumour blood flow modification in two rat tumour systems using endothelin-1 and angiotensin II: influence of tumour size on angiotensin II response | Q47324896 | ||
| Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. | Q47334417 | ||
| Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients | Q48487650 | ||
| Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients | Q49015944 | ||
| Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma | Q49134863 | ||
| FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience | Q24622390 | ||
| The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance | Q26746986 | ||
| Molecular pathways: hypoxia response in immune cells fighting or promoting cancer | Q26829571 | ||
| Clinical biomarkers of response in advanced renal cell carcinoma | Q26852564 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Cancer and liver cirrhosis: implications on prognosis and management | Q28068579 | ||
| Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia | Q28085029 | ||
| International union of pharmacology. XXIII. The angiotensin II receptors | Q28138041 | ||
| Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer | Q28168748 | ||
| Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research | Q28272171 | ||
| TGF-beta: a master of all T cell trades | Q28290413 | ||
| T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation | Q28595069 | ||
| 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) | Q29617334 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy | Q30388746 | ||
| Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia | Q30399006 | ||
| Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers | Q30542073 | ||
| Disparate responses of tumour vessels to angiotensin II: tumour volume-dependent effects on perfusion and oxygenation | Q31791086 | ||
| A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. | Q33407858 | ||
| Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients | Q33588739 | ||
| Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials | Q33803829 | ||
| The role of mechanical forces in tumor growth and therapy | Q33942378 | ||
| Fibroblast heterogeneity in the cancer wound | Q33964324 | ||
| Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages | Q34044797 | ||
| History of the design of captopril and related inhibitors of angiotensin converting enzyme | Q34097139 | ||
| Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation | Q34163525 | ||
| How the antihypertensive losartan was discovered | Q34333622 | ||
| Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine | Q34363486 | ||
| Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer | Q34387974 | ||
| The effect of calcium channel blockers on the outcome of acute myeloid leukemia | Q34422254 | ||
| 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut | Q34527664 | ||
| Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice | Q34533019 | ||
| Physiology of local renin-angiotensin systems. | Q34543927 | ||
| Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors | Q34582878 | ||
| Angiotensin-converting enzyme is required for normal myelopoiesis | Q34682525 | ||
| Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use | Q36932703 | ||
| Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer | Q37013337 | ||
| Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy | Q37072889 | ||
| Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer | Q37109214 | ||
| Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes | Q37121758 | ||
| Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy | Q37161504 | ||
| The renin-angiotensin system and malignancy | Q37218569 | ||
| Exposure to ACEI/ARB and β-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer | Q37236007 | ||
| Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy | Q37246492 | ||
| Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels | Q37250548 | ||
| Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. | Q37340643 | ||
| Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models | Q37492629 | ||
| Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7) | Q37505197 | ||
| Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib | Q37519031 | ||
| Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy | Q37670234 | ||
| Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer | Q37705334 | ||
| Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis | Q37767028 | ||
| The renin-angiotensin system and cancer: old dog, new tricks. | Q37802186 | ||
| Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals | Q37847949 | ||
| Cancer-related inflammation: common themes and therapeutic opportunities | Q37972525 | ||
| The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. | Q34690091 | ||
| The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis | Q35050809 | ||
| Rapid vascular regrowth in tumors after reversal of VEGF inhibition | Q35052385 | ||
| VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors | Q35064894 | ||
| G-protein coupled receptors of the renin-angiotensin system: new targets against breast cancer? | Q35089791 | ||
| Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts | Q35093193 | ||
| Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function | Q35114429 | ||
| Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer | Q35114450 | ||
| Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort | Q35131970 | ||
| Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma | Q35176774 | ||
| Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination | Q35219246 | ||
| Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression. | Q35388346 | ||
| The carboxypeptidase ACE shapes the MHC class I peptide repertoire | Q35402189 | ||
| CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice | Q35528287 | ||
| Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. | Q35680814 | ||
| Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma | Q35681985 | ||
| Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. | Q35855609 | ||
| The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis | Q36012076 | ||
| Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. | Q36051199 | ||
| COX-2: a molecular target for colorectal cancer prevention | Q36101515 | ||
| Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. | Q36134167 | ||
| Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib | Q36193678 | ||
| Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients | Q36335456 | ||
| Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy | Q36378276 | ||
| Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy | Q36414978 | ||
| Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC. | Q36587690 | ||
| Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival | Q36613817 | ||
| Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. | Q36639793 | ||
| Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug | Q36688756 | ||
| Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. | Q36755237 | ||
| Predictors of distant metastasis and mortality in patients with stage II colorectal cancer | Q36765672 | ||
| Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. | Q36783072 | ||
| Vascular normalization as an emerging strategy to enhance cancer immunotherapy | Q36847357 | ||
| Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study | Q36916770 | ||
| Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial | Q36932216 | ||
| Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. | Q50758365 | ||
| Angiotensin II Enhances Proliferation and Inflammation through AT1/PKC/NF-x03BA;B Signaling Pathway in Hepatocellular Carcinoma Cells. | Q51693343 | ||
| Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. | Q52325069 | ||
| Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Q52847414 | ||
| The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. | Q52925750 | ||
| Regulation of colorectal cancer cell epithelial to mesenchymal transition by the renin angiotensin system. | Q52980831 | ||
| Prognostic Impact of Renin-Angiotensin Inhibitors in Patients with Bladder Cancer Undergoing Radical Cystectomy. | Q53011547 | ||
| How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?. | Q53140602 | ||
| Prognostic Impact of Renin-Angiotensin System Blockade on Renal Cell Carcinoma After Surgery. | Q53612763 | ||
| Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. | Q54500899 | ||
| Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials | Q56658918 | ||
| Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes | Q60169563 | ||
| Negative regulation of VEGF-induced vascular leakage by blockade of angiotensin II type 1 receptor. | Q64973635 | ||
| Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis | Q73407127 | ||
| Pre-exposure to oxidative stress decreases the nuclear factor-kappa B-dependent transcription in T lymphocytes | Q74506201 | ||
| Modulation of angiotensin-converting enzyme in cultured human vascular endothelial cells | Q77157569 | ||
| Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer | Q79643576 | ||
| Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy | Q81364065 | ||
| Angiotensin blockade in diabetic patients decreases insulin resistance-associated low-grade inflammation | Q82981754 | ||
| Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer | Q83375724 | ||
| Efficacy of angiotensin-receptor blockers on demographic and clinico-pathological characteristics of breast cancer | Q83426056 | ||
| Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma | Q83438325 | ||
| Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy | Q83739387 | ||
| Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1 | Q83929207 | ||
| Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins | Q84971321 | ||
| An FDA overview of rodent carcinogenicity studies of angiotensin II AT-1 receptor blockers: pulmonary adenomas and carcinomas | Q85314969 | ||
| The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients | Q85965147 | ||
| Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study | Q86054283 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 410 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| renin–angiotensin system | Q898218 | ||
| neoplasm | Q1216998 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2017-10-01 | |
| 2017-10-04 | |||
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy | |
| P478 | volume | 9 |
| Q93088071 | 18 F-Labeled Derivatives of Irbesartan for Angiotensin II Receptor PET Imaging |
| Q92932998 | A framework for advancing our understanding of cancer-associated fibroblasts |
| Q92899471 | AGTR1 promotes lymph node metastasis in breast cancer by upregulating CXCR4/SDF-1α and inducing cell migration and invasion |
| Q91857825 | Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies |
| Q99619108 | Angiotensin II enhances the proliferation of Natural Killer/T-cell lymphoma cells via activating PI3K/Akt signaling pathway |
| Q52342055 | Angiotensin-converting enzyme in innate and adaptive immunity. |
| Q64122327 | Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis |
| Q98626252 | COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making |
| Q92809073 | Combined Effects of Eicosapentaenoic Acid and Adipocyte Renin-Angiotensin System Inhibition on Breast Cancer Cell Inflammation and Migration |
| Q89517466 | Combining microenvironment normalization strategies to improve cancer immunotherapy |
| Q91827317 | EXPRESSION OF THE RENIN-ANGIOTENSIN SYSTEM COMPONENTS IN ONCOLOGIC DISEASES |
| Q55190117 | Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. |
| Q91310928 | Fibroblasts Fuel Immune Escape in the Tumor Microenvironment |
| Q91526523 | Fluids and their mechanics in tumour transit: shaping metastasis |
| Q91709046 | High-salt diet inhibits tumour growth in mice via regulating myeloid-derived suppressor cell differentiation |
| Q64241125 | Identification of the Transcriptional Networks and the Involvement in Angiotensin II-Induced Injury after CRISPR/Cas9-Mediated Knockdown of Cyr61 in HEK293T Cells |
| Q92434452 | Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives |
| Q89602909 | Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges |
| Q58704728 | Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? |
| Q90373718 | Mechanical confinement via a PEG/Collagen interpenetrating network inhibits behavior characteristic of malignant cells in the triple negative breast cancer cell line MDA.MB.231 |
| Q57063523 | Novel F-Labeled PET Imaging Agent FV45 Targeting the Renin-Angiotensin System |
| Q92989291 | Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma |
| Q64979278 | Phasic Left Atrial Function in Cancer Patients Before Initiation of Anti-Cancer Therapy. |
| Q89537494 | Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World |
| Q93068290 | Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort |
| Q64107775 | Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability |
| Q52615294 | Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. |
| Q53699572 | Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy. |
| Q58084993 | Regularization and grouping -omics data by GCA method: A transcriptomic case |
| Q49947511 | Renin angiotensin system and its role in biomarkers and treatment in gliomas |
| Q96174506 | Renin angiotensin system inhibition attenuates adipocyte-breast cancer cell interactions |
| Q88248824 | Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events |
| Q59125636 | Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity |
| Q89640256 | Renin-angiotensin inhibitors were associated with improving outcomes of hepatocellular carcinoma with primary hypertension after hepatectomy |
| Q92109812 | Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies |
| Q91651395 | Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy |
| Q92028224 | Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension |
| Q90436245 | Review article: systemic treatment of hepatocellular carcinoma |
| Q98172049 | SARS-CoV-2 and cancer: Are they really partners in crime? |
| Q89623490 | Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments |
| Q89761451 | Targeting Tumors Using Peptides |
| Q92802002 | Therapeutic Targeting of Cancer Stem Cells via Modulation of the Renin-Angiotensin System |
| Q92252037 | Tissue ACE phenotyping in lung cancer |
| Q98156799 | Withaferin A attenuates ovarian cancer-induced cardiac cachexia |
Search more.